Armstrong Henry H Associates Inc. Has $314,000 Position in Amgen Inc. (NASDAQ:AMGN)

Armstrong Henry H Associates Inc. grew its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 27.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,106 shares of the medical research company’s stock after purchasing an additional 235 shares during the period. Armstrong Henry H Associates Inc.’s holdings in Amgen were worth $314,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. BOK Financial Private Wealth Inc. bought a new position in Amgen in the 4th quarter worth approximately $29,000. United Community Bank acquired a new position in Amgen in the fourth quarter valued at about $29,000. Planned Solutions Inc. bought a new position in shares of Amgen during the 4th quarter valued at about $30,000. Delos Wealth Advisors LLC increased its stake in Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Finally, Providence Capital Advisors LLC bought a new position in Amgen in the third quarter valued at approximately $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock traded down $1.73 during trading hours on Friday, hitting $308.16. The company had a trading volume of 6,933,277 shares, compared to its average volume of 2,019,282. The firm has a 50-day moving average of $296.57 and a 200 day moving average of $290.69. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The firm has a market cap of $165.31 billion, a PE ratio of 44.02, a PEG ratio of 2.80 and a beta of 0.60. Amgen Inc. has a one year low of $218.44 and a one year high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the previous year, the company posted $3.98 EPS. The firm’s quarterly revenue was up 22.0% on a year-over-year basis. On average, sell-side analysts expect that Amgen Inc. will post 19.47 earnings per share for the current year.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Mizuho raised their price objective on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Royal Bank of Canada upped their price objective on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a research report on Friday, June 14th. Morgan Stanley boosted their target price on Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday, May 3rd. Barclays raised shares of Amgen from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, UBS Group increased their target price on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $305.85.

Get Our Latest Analysis on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.